Behind the science
'Putting patients first means caring about the air they breathe'
Climate change and air pollution negatively impact the health of patients with respiratory conditions – and yet some treatments used for those same conditions contribute to greenhouse gas emissions. Here, Dr David Lipson, GSK’s Vice President and Clinical Research Head, Respiratory and Immunology R&D, explains why a focus on sustainability in respiratory care is therefore essential – and how GSK is innovating to benefit both patients and the planet.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Behind the science